Table 1 Patients’ Characteristics at baseline
|  | All patients (n = 102) |
|---|---|
Age, median (range), years | 74 (48–96) |
PSA, median (range), ng/ml | 15.8 (0.008–2082) |
Gleason score, No. (%) | |
  6–7 | 18 (17.6) |
  8–10 | 80 (78.4) |
  Unknown | 4 (3.9) |
Metastasis, No. (%) | |
  Yes | 94 (92.2) |
  No | 8 (7.8) |
Site of Metastasis, No. (%) | |
  Lymph node | 58 (56.9) |
  Bone | 80 (78.4) |
  Lung | 16 (15.7) |
  Liver | 8 (7.8) |
  Other | 6 (5.9) |
ECOG PS, No. (%) | |
  0–1 | 73 (71.6) |
  ≥2 | 29 (28.4) |
Time from starting ADT, median (range), months | 55.9 (4.1–207.6) |
Time from CRPC diagnosis, median (range), months | 24.0 (0–140.7) |
Hemoglobin | |
  Median (range), g/dl | 12.4 (6.6–15.7) |
  <LLN No. (%) | 19 (18.6) |
ALP | |
  Median (range), U/L | 275.5 (78–3208) |
  ≥360, No. (%) | 32 (31.4) |
LDH | |
  Median (range), U/L | 204 (77–2280) |
  ≥227, No. (%) | 29 (28.4) |
Treatment immediately prior to baseline sample collection, No. (%) | |
  Hormone therapy | |
   Bicalutamide | 16 (15.7) |
   Flutamide | 17 (16.7) |
   Estramustine phosphate | 7 (6.9) |
   Abiraterone | 20 (19.6) |
   Enzalutamide | 21 (20.6) |
   Others | 10 (9.8) |
  Chemotherapy | |
   Docetaxel | 5 (4.9) |
   Cabazitaxel | 4 (3.9) |
   Paclitaxel and Carboplatin | 2 (2.0) |
No. of resistance to anti-androgen therapy/chemotherapy, median (range) | 3 (0–9) |
Resistance to each treatment, No. (%) | |
  Hormone therapy |  |
   Bicalutamide | 99 (97.1) |
   Flutamide | 65 (63.7) |
   Estramustine phosphate | 35 (34.3) |
   Abiraterone | 30 (29.4) |
   Enzalutamide | 32 (31.4) |
   Others | 23 (22.5) |
  Chemotherapy | |
   Docetaxel | 27 (26.5) |
   Cabazitaxel | 5 (4.9) |
   Paclitaxel and Carboplatin | 3 (2.9) |
